PL346796A1 - Methods of downmodulating the immune response to therapeutic proteins - Google Patents

Methods of downmodulating the immune response to therapeutic proteins

Info

Publication number
PL346796A1
PL346796A1 PL99346796A PL34679699A PL346796A1 PL 346796 A1 PL346796 A1 PL 346796A1 PL 99346796 A PL99346796 A PL 99346796A PL 34679699 A PL34679699 A PL 34679699A PL 346796 A1 PL346796 A1 PL 346796A1
Authority
PL
Poland
Prior art keywords
downmodulating
methods
immune response
therapeutic proteins
proteins
Prior art date
Application number
PL99346796A
Other languages
English (en)
Inventor
Jiahua Qian
Leon W Hoyer
Mary Collins
Gary S Gray
Original Assignee
Genetics Inst
American Nat Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, American Nat Red Cross filed Critical Genetics Inst
Publication of PL346796A1 publication Critical patent/PL346796A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL99346796A 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins PL346796A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21

Publications (1)

Publication Number Publication Date
PL346796A1 true PL346796A1 (en) 2002-02-25

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99346796A PL346796A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Country Status (21)

Country Link
EP (1) EP1115423A1 (lt)
JP (1) JP2002526455A (lt)
KR (1) KR20010085830A (lt)
CN (1) CN1331602A (lt)
AU (1) AU761206B2 (lt)
BR (1) BR9913991A (lt)
CA (1) CA2343916A1 (lt)
CZ (1) CZ20011021A3 (lt)
EA (1) EA005236B1 (lt)
HK (1) HK1039059A1 (lt)
HU (1) HUP0103960A3 (lt)
IL (1) IL142069A0 (lt)
LT (1) LT4920B (lt)
LV (1) LV12768B (lt)
MX (1) MXPA01002898A (lt)
NO (1) NO20011412L (lt)
NZ (1) NZ511034A (lt)
PL (1) PL346796A1 (lt)
SI (1) SI20626A (lt)
WO (1) WO2000016801A1 (lt)
ZA (1) ZA200103156B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE60118362T2 (de) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
EP1636579A4 (en) * 2003-06-10 2011-10-05 Smiths Detection Inc SENSOR ASSEMBLY
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
CA2580812A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
EP0776217A1 (en) * 1994-08-19 1997-06-04 Novo Nordisk A/S A method of treating a patient with a biologically active compound
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
PL193966B1 (pl) * 1997-01-10 2007-04-30 Biogen Idec Ma Zastosowanie przeciwciał przeciwko CD40L lub pochodnych
CN1261285A (zh) * 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗
US8151477B2 (en) 2009-11-06 2012-04-10 Hexagon Metrology Ab CMM with modular functionality

Also Published As

Publication number Publication date
KR20010085830A (ko) 2001-09-07
EA005236B1 (ru) 2004-12-30
NO20011412L (no) 2001-05-16
LT4920B (lt) 2002-06-25
LV12768A (en) 2001-12-20
LV12768B (lv) 2002-06-20
CN1331602A (zh) 2002-01-16
BR9913991A (pt) 2001-07-03
CZ20011021A3 (cs) 2001-10-17
MXPA01002898A (es) 2002-06-04
JP2002526455A (ja) 2002-08-20
NO20011412D0 (no) 2001-03-20
HK1039059A1 (zh) 2002-04-12
HUP0103960A3 (en) 2003-09-29
LT2001045A (lt) 2002-01-25
EA200100385A1 (ru) 2001-10-22
WO2000016801A1 (en) 2000-03-30
AU761206B2 (en) 2003-05-29
CA2343916A1 (en) 2000-03-30
IL142069A0 (en) 2002-03-10
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (hu) 2002-02-28
SI20626A (sl) 2002-02-28
ZA200103156B (en) 2002-07-18
AU6057899A (en) 2000-04-10
WO2000016801A9 (en) 2000-10-26
NZ511034A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
AP2000001983A0 (en) Antibodies to cd23 derivatives thereof and their therapeutic uses
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
ID28111A (id) Metoda untuk meningkatkan kesehatan kulit
FI971332A7 (fi) Suihkukuivatut mikropartikkelit terapeuttisina vehikkeleinä
IL135673A0 (en) Therapeutic uses of quinoline derivatives
EP1033994A4 (en) METHOD FOR PRODUCING BIOGINKGO
ID28441A (id) Terapi untuk memperbaiki kesadaran
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
GB9930443D0 (en) Novel use of heat shock proteins
IL142069A0 (en) Methods of downmodulating the immune response to therapeutic proteins
IL141551A0 (en) Compositions and methods for the treatment of immune related diseases
ID24759A (id) Metoda untuk meningkatkan volume tulang
GB9822619D0 (en) Immune response stimulation
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
GB2329384B (en) Preparation of 1-chloro-1-cyclopropylethene
KR960025637U (ko) 간격조절이 용이한 콘넥터
NO965332D0 (no) Terapeutisk perparat
GB9820388D0 (en) Improvements relating to furniture
TW315720U (en) Structure of treadmill also having the resupination function of human body
KR960013110U (ko) 신발의 바닥면에 착탈이 용이한 지압구
GB9606255D0 (en) The game of bridge companion
TW322782U (en) Structure improvement of walker
TW351186U (en) Improvement of exercise walker
TW369896U (en) Modified walker structure

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)